Lenvatinib (E7080/MK-7902) 联合 Pembrolizumab (MK-3475) 对比标准化疗和 Lenvatinib 单药治疗铂类治疗和免疫治疗后进展的复发/转移性头颈部鳞状细胞癌 (MK-7902-009/ E7080-G000-228/LEAP-009)
一项评估乐伐替尼 (E7080/MK-7902) 联合派姆单抗 (MK-3475) 与标准护理化疗和乐伐替尼单药治疗复发性参与者的安全性和有效性的 2 期、随机、开放标签三臂临床研究/在铂类疗法和免疫疗法(PD-1/PD-L1 抑制剂)后进展的转移性头颈部鳞状细胞癌 (R/M HNSCC) (LEAP-009)
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse.
The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have a better overall survival rate than people who receive standard chemotherapy treatment.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
With Amendment 7, participants will discontinue lenvatinib and pembrolizumab and lenvatinib monotherapy, unless discussed with the Sponsor.
A protocol-specified periodic safety review was completed with a data cut-off of 31-May-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure. Per protocol, 34 participants enrolled after the primary completion date and will be analyzed in the End of Trial analysis.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段2
联系人和位置
学习地点
-
-
Capital Region
-
Copenhagen、Capital Region、丹麦、2100
- Rigshospitalet University Hospital Copenhagen ( Site 1000)
-
-
-
-
-
Beersheba、以色列、8400000
- Soroka Medical Center-Oncology ( Site 0604)
-
Haifa、以色列、3109601
- Rambam Health Care Campus-Oncology Division ( Site 0602)
-
Jerusalem、以色列、9112001
- Hadassah Medical Center. Ein Kerem ( Site 0601)
-
Ramat Gan、以色列、5265601
- Chaim Sheba Medical Center ( Site 0600)
-
-
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0304)
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 4E6
- BC Cancer-Vancouver Center ( Site 0306)
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8V 5C2
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0307)
-
Toronto、Ontario、加拿大、M4N 3M5
- Sunnybrook Research Institute ( Site 0308)
-
-
-
-
-
Kaohsiung City、台湾、83301
- Chang Gung Medical Foundation - Kaohsiung ( Site 1204)
-
Taichung、台湾、404332
- China Medical University Hospital ( Site 1205)
-
Taichung、台湾、407
- Taichung Veterans General Hospital ( Site 1206)
-
Tainan、台湾、704
- National Cheng Kung University Hospital ( Site 1202)
-
Taipei、台湾、10048
- National Taiwan University Hospital ( Site 1200)
-
Taipei、台湾、11217
- Taipei Veterans General Hospital ( Site 1201)
-
Taoyuan、台湾、333
- Chang Gung Memorial Hospital - Linkou Branch ( Site 1203)
-
-
-
-
Antioquia
-
Medellín、Antioquia、哥伦比亚、50034
- Instituto de Cancerología ( Site 0408)
-
-
Cesar Department
-
Valledupar、Cesar Department、哥伦比亚、200001
- Sociedad De Oncologia Y Hematologia Del Cesar ( Site 0404)
-
-
Cundinamarca
-
Bogotá、Cundinamarca、哥伦比亚、110221
- Administradora Country S.A.S - Clínica del Country ( Site 0407)
-
-
Departamento de Córdoba
-
Montería、Departamento de Córdoba、哥伦比亚、230002
- IMAT S.A.S ( Site 0409)
-
-
-
-
-
São Paulo、巴西、01509-010
- A. C. Camargo Cancer Center ( Site 0809)
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、91350-200
- Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0806)
-
-
-
-
-
Oslo、挪威、0379
- Oslo universitetssykehus, Radiumhospitalet ( Site 1102)
-
-
-
-
-
Paris、法国、75005
- Institut Curie ( Site 0500)
-
-
Bouches-du-Rhone
-
Marseille、Bouches-du-Rhone、法国、13385
- Hopital La Timone ( Site 0503)
-
-
Herault
-
Montpellier、Herault、法国、34070
- Centre de Cancerologie du Grand Montpellier ( Site 0508)
-
-
Puy-de-Dome
-
Clermont-Ferrand、Puy-de-Dome、法国、63003
- Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 0510)
-
-
Seine-Maritime
-
Rouen、Seine-Maritime、法国、76038
- Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0509)
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、法国、94800
- Institut Gustave Roussy ( Site 0505)
-
-
-
-
New South Wales
-
Port Macquarie、New South Wales、澳大利亚、2444
- Mid North Coast Cancer Institute ( Site 0109)
-
Sydney、New South Wales、澳大利亚、2148
- Blacktown Hospital ( Site 0101)
-
-
Queensland
-
Douglas、Queensland、澳大利亚、4814
- The Townsville Hospital ( Site 0107)
-
Greenslopes、Queensland、澳大利亚、4120
- Gallipoli Medical Research Ltd-GMRF CTU ( Site 0105)
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- Royal Adelaide Hospital ( Site 0110)
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- Monash Health ( Site 0102)
-
-
-
-
Bucharest
-
Bucharest、Bucharest、罗马尼亚、013823
- MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 1703)
-
Bucharest、Bucharest、罗马尼亚、030171
- Spitalul Clinic Colțea ( Site 1708)
-
-
Cluj
-
Cluj-Napoca、Cluj、罗马尼亚、400015
- Cardiomed SRL Cluj-Napoca ( Site 1701)
-
Cluj-Napoca、Cluj、罗马尼亚、400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1702)
-
Floreşti、Cluj、罗马尼亚、407280
- S.C. Radiotherapy Center Cluj S.R.L ( Site 1706)
-
-
Dolj
-
Craiova、Dolj、罗马尼亚、200542
- S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1704)
-
-
Timiș County
-
Timișoara、Timiș County、罗马尼亚、300239
- Cabinet Medical Oncomed ( Site 1707)
-
-
-
-
California
-
Duarte、California、美国、91010
- City of Hope ( Site 1519)
-
Los Angeles、California、美国、90095
- UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568)
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- Yale-New Haven Hospital-Yale Cancer Center ( Site 1505)
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- Georgetown University Medical Center ( Site 1520)
-
-
Florida
-
Gainesville、Florida、美国、32608
- UF Health ( Site 1554)
-
Orange City、Florida、美国、32763
- Mid Florida Hematology and Oncology Center ( Site 1606)
-
Weston、Florida、美国、33331
- Cleveland Clinic Florida ( Site 1596)
-
-
Georgia
-
Augusta、Georgia、美国、30912
- Georgia Cancer Center at Augusta University ( Site 1575)
-
Marietta、Georgia、美国、30060
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1521)
-
Savannah、Georgia、美国、31404
- Memorial Health University Medical Center ( Site 1626)
-
-
Idaho
-
Post Falls、Idaho、美国、83854
- Beacon Cancer Care ( Site 1599)
-
-
Illinois
-
Chicago、Illinois、美国、60607
- Rush University Medical Center ( Site 1560)
-
Evanston、Illinois、美国、60201
- NorthShore University HealthSystem - Evanston Hospital ( Site 1614)
-
-
Indiana
-
Muncie、Indiana、美国、47303
- IU Health Ball Memorial Hospital, Inc.-IU Health Ball Memorial Cancer Center ( Site 1612)
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa ( Site 1572)
-
-
Kansas
-
Westwood、Kansas、美国、66205
- University of Kansas Cancer Center ( Site 1538)
-
-
Kentucky
-
Louisville、Kentucky、美国、40205
- Norton Hospital-Norton Cancer Institute - Downtown ( Site 1601)
-
Paducah、Kentucky、美国、42003
- Mercy Health-Paducah Cancer Center ( Site 1623)
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- Our Lady of the Lake RMC-Clinical Research ( Site 1624)
-
Baton Rouge、Louisiana、美国、70809
- Mary Bird Perkins Cancer Center Baton Rouge ( Site 1622)
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- University of Maryland Greenebaum Cancer Center ( Site 1522)
-
-
Massachusetts
-
Boston、Massachusetts、美国、02118
- Boston Medical Center ( Site 1605)
-
Worcester、Massachusetts、美国、01655
- University of Massachusetts Chan Medical School ( Site 1616)
-
-
Michigan
-
Ann Arbor、Michigan、美国、48105
- VA Ann Arbor Healthcare System ( Site 1584)
-
Detroit、Michigan、美国、48201
- Barbara Ann Karmanos Cancer Institute ( Site 1566)
-
Detroit、Michigan、美国、48202
- Henry Ford Health System ( Site 1544)
-
-
Mississippi
-
Hattiesburg、Mississippi、美国、39401
- Hattiesburg Clinic ( Site 1515)
-
Jackson、Mississippi、美国、39202
- Jackson Oncology Associates, PLLC-Clinical Trials ( Site 1625)
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine ( Site 1500)
-
-
Montana
-
Billings、Montana、美国、59102
- St. Vincent Frontier Cancer Center ( Site 1507)
-
-
Nebraska
-
Omaha、Nebraska、美国、68105
- University Of Nebraska Medical Center ( Site 1570)
-
Omaha、Nebraska、美国、68130
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 1627)
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1555)
-
New Brunswick、New Jersey、美国、08901
- Rutgers Cancer Institute of New Jersey ( Site 1523)
-
-
New York
-
Mineola、New York、美国、11501
- Perlmutter Cancer Center at Winthrop Oncology Hematology Associates NYU Langone Health ( Site 1597)
-
New York、New York、美国、10016
- Laura and Isaac Perlmutter Cancer Center ( Site 1582)
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Levine Cancer Institute ( Site 1590)
-
Durham、North Carolina、美国、27710
- Duke Cancer Institute ( Site 1541)
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- University of Cincinnati Medical Center ( Site 1567)
-
Cleveland、Ohio、美国、44106
- University Hospital Cleveland ( Site 1578)
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Main ( Site 1598)
-
Columbus、Ohio、美国、43210
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 1558)
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74146
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1508)
-
-
Pennsylvania
-
Gettysburg、Pennsylvania、美国、17325
- Gettysburg Cancer Center ( Site 1594)
-
Hershey、Pennsylvania、美国、17033
- Penn State Hershey Medical Center ( Site 1561)
-
Philadelphia、Pennsylvania、美国、19111
- Fox Chase Cancer Center ( Site 1502)
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina ( Site 1579)
-
Greenville、South Carolina、美国、29607
- St Francis Cancer Center-Research Office ( Site 1607)
-
-
Texas
-
Fort Worth、Texas、美国、76104
- The Center For Cancer And Blood Disorders ( Site 1569)
-
-
Utah
-
Salt Lake City、Utah、美国、84106
- Utah Cancer Specialists ( Site 1621)
-
Salt Lake City、Utah、美国、84112
- Huntsman Cancer Institute ( Site 1532)
-
-
Virginia
-
Fairfax、Virginia、美国、22031-4867
- Inova Schar Cancer Institute ( Site 1550)
-
Fredericksburg、Virginia、美国、22408
- Hematology Oncology Associates of Fredericksburg ( Site 1537)
-
-
Washington
-
Tacoma、Washington、美国、98405
- MultiCare Health System-MultiCare Oncology - Puget Sound ( Site 1609)
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Medical College of Wisconsin Clinical Cancer Center ( Site 1574)
-
-
-
-
-
Manchester、英国、m20 4bx
- The Christie NHS Foundation Trust ( Site 0907)
-
-
Aberdeen City
-
Aberdeen、Aberdeen City、英国、AB25 2ZN
- Aberdeen Royal Infirmary ( Site 0911)
-
-
East Riding Of Yorkshire
-
Cottingham、East Riding Of Yorkshire、英国、HU16 5JQ
- Castle Hill Hospital ( Site 0910)
-
-
Glasgow City
-
Glasgow、Glasgow City、英国、G12 0YN
- The Beatson West of Scotland Cancer Centre ( Site 0909)
-
-
Great Britain
-
London、Great Britain、英国、SE1 9RT
- Guy s and St Thomas Hospital NHS Foundation Trust ( Site 0903)
-
-
Hampshire
-
Southampton、Hampshire、英国、SO16 6YD
- University Hospital Southampton NHS Foundation Trust ( Site 0905)
-
-
London, City of
-
London、London, City of、英国、SW3 6JJ
- Royal Marsden Hospital ( Site 0902)
-
London、London, City of、英国、W6 8RF
- Charing Cross Hospital ( Site 0908)
-
-
Somerset
-
Taunton、Somerset、英国、TA1 5DA
- Musgrove Park Hospital ( Site 0904)
-
-
Surrey
-
Sutton、Surrey、英国、SM2 5PT
- Royal Marsden Hospital. ( Site 0901)
-
-
-
-
-
Porto、葡萄牙、4200-072
- Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 1400)
-
-
Porto District
-
Vila Nova de Gaia、Porto District、葡萄牙、4434-502
- Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 1401)
-
-
-
-
-
Barcelona、西班牙、08035
- Hospital Universitari Vall d Hebron ( Site 0701)
-
Madrid、西班牙、28034
- Hospital Ramon y Cajal ( Site 0705)
-
Málaga、西班牙、29010
- Hospital Virgen de la Victoria ( Site 0702)
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、西班牙、08908
- Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0700)
-
-
Catalonia
-
Barcelona、Catalonia、西班牙、08036
- HOSPITAL CLÍNIC DE BARCELONA ( Site 0707)
-
-
Galicia
-
A Coruña、Galicia、西班牙、15009
- Centro Oncologico de Galicia ( Site 0706)
-
-
Valenciana, Comunitat
-
Valencia、Valenciana, Comunitat、西班牙、46014
- Hospital General de Valencia ( Site 0703)
-
-
-
-
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System ( Site 1800)
-
Seoul、韩国、06351
- Samsung Medical Center ( Site 1803)
-
-
Kyonggi-do
-
Seongnam、Kyonggi-do、韩国、13620
- Seoul National University Bundang Hospital ( Site 1801)
-
Suwon、Kyonggi-do、韩国、16499
- Ajou University Hospital ( Site 1802)
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Pathologically confirmed recurrent (not amenable to curative treatment with local and/or systemic therapies) or metastatic (disseminated) head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies
-
Disease progression at any time during or after treatment with a platinum-containing (e.g., carboplatin or cisplatin) regimen
-
Disease progression on or after treatment with a programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb)
-
Pre-study imaging that demonstrates evidence of disease progression based on investigator review of at least 2 pre-study images per RECIST 1.1, following initiation of treatment with a PD-1/PD-L1 inhibitor
-
Measurable disease by computed tomography scan (CT) or magnetic resonance imaging (MRI) based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as verified by blinded independent central review (BICR). Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of the first dose of study intervention
-
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 1 week after the last dose of lenvatinib, 3 months after the last dose of capecitabine and paclitaxel, and 6 months after the last dose of docetaxel:
- Refrain from donating sperm
- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception unless confirmed to be azoospermic
- Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
-
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- Is not a woman of childbearing potential (WOCBP)
- Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab or 1 month post lenvatinib, whichever occurs last (Arms 1 and 3), or during the intervention period and for at least 6 months after the last dose of capecitabine, docetaxel, paclitaxel; and 2 months after the last dose of cetuximab (Arm 2)
- Female participants who randomize to Arm 2 must also agree not to donate or freeze/store eggs during the intervention period and for at least 6 months after the last dose of capecitabine, docetaxel, paclitaxel; and 2 months after the last dose of cetuximab
-
Adequately controlled blood pressure (BP) with or without antihypertensive medications
-
Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
-
Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
-
Adequate organ function
Exclusion Criteria:
- Disease that is suitable for local therapy administered with curative intent
- Life expectancy of less than 3 months and/or has rapidly progressing disease in the opinion of the treating investigator
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, or has current pneumonitis/interstitial lung disease
- Active infection requiring systemic therapy
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Known additional malignancy that is progressing or has required active systemic treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ that have undergone potentially curative therapy
- Active autoimmune disease that has required systemic treatment in the past 2 years
- Had an allogeneic tissue/solid organ transplant
- Known history of human immunodeficiency virus (HIV) infection
- History of any contraindication or has a severe hypersensitivity to any components of pembrolizumab, lenvatinib or SOC chemotherapy.
- Pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
- History of a gastrointestinal malabsorption or any other condition or procedure that may affect oral study drug absorption
- Had major surgery within 3 weeks prior to first dose of study interventions
- Clinically significant cardiovascular impairment within 12 months of the first dose of study drug
- Active tuberculosis
- Has difficulty swallowing capsules or ingesting a suspension orally, or by a feeding tube
- Prior treatment with lenvatinib
- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or has not recovered from adverse events (AEs) due to a previously administered agent. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible
- Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines is allowed
- Previously treated with 4 or more systemic regimens given for recurrent/metastatic disease
- Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
- Known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Lenvatinib + Pembrolizumab
Participants will be treated with the combination of lenvatinib (once daily 20 mg oral dose) plus pembrolizumab (200 mg 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle for 35 cycles), until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib. |
20 mg once daily, taken as oral capsules
其他名称:
200 mg 30-minute IV infusion on day 1 of each 21-day cycle
其他名称:
24 mg once daily, taken as oral capsules
其他名称:
|
|
有源比较器:SOC Chemotherapy
Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. |
75 mg/m^2 administered as an IV infusion on day 1 of each 21-day cycle
其他名称:
1250 mg/m^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
其他名称:
80 mg/m^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
其他名称:
400 mg/m^2 loading dose, followed by 250 mg/m^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
其他名称:
|
|
有源比较器:Lenvatinib Monotherapy
Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. |
20 mg once daily, taken as oral capsules
其他名称:
24 mg once daily, taken as oral capsules
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:Up to approximately 45 months
|
OS was defined as the time from randomization to death due to any cause. |
Up to approximately 45 months
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS)
大体时间:Up to approximately 45 months
|
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. |
Up to approximately 45 months
|
|
Objective Response Rate (ORR)
大体时间:Up to approximately 45 months
|
ORR was defined as the percentage of participants who had a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. |
Up to approximately 45 months
|
|
Duration of Response (DOR)
大体时间:Up to approximately 55 months
|
DOR was defined as the time from the first documented evidence of complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR. |
Up to approximately 55 months
|
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
大体时间:Up to approximately 55 months
|
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE was presented. |
Up to approximately 55 months
|
|
Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)
大体时间:Up to approximately 55 months
|
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE was presented. |
Up to approximately 55 months
|
合作者和调查者
调查人员
调查人员
- 研究主任:Medical Director、Merck Sharp & Dohme LLC
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- 7902-009
- LEAP-009 (其他标识符:MSD)
- E7080-G000-228 (其他标识符:Eisai)
- MK-7902-009 (其他标识符:MSD)
- 2019-000569-19 (EudraCT编号)
- U1111-1278-2707 (注册表标识符:UTN)
- 2022-500820-31-00 (注册表标识符:EU CT)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.